Norbert Riedel, Ph.D.

President and Chief Executive Officer, Aptinyx

Dr. Norbert Riedel is President and Chief Executive Officer of Aptinyx, as well as a member of the company’s Board of Directors.

Norbert was formerly President and Chief Executive Officer of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, he served various roles at Baxter International, including Corporate Vice President and Chief Science and Innovation Officer. Previously, he was Head of Worldwide Biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). He is an adjunct professor at Boston University School of Medicine and Northwestern University’s Feinberg School of Medicine and, prior to moving into industry, was an Associate Professor of Medicine at Boston University School of Medicine and a Visiting Professor at the Massachusetts Institute of Technology.

Norbert serves on the boards of Jazz Pharmaceuticals and the Illinois Biotechnology Innovation Organization. He served on the Board of Directors of Ariad Pharmaceuticals until the company was acquired in February 2017. He is a member of the Austrian Academy of Sciences and served on Governor Pat Quinn’s Illinois Innovation Council.

Norbert received a bachelor’s degree and Ph.D. from the University of Frankfurt and was a postdoctoral fellow at Harvard University.